We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sagimet Biosciences

News List

ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China prnasia
November 19, 2020
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial in China.
Sagimet Announces Positive Results in NASH Trial of FASN Inhibitor TVB-2640 americanpharmaceuticalreview
June 29, 2020
Sagimet Biosciences announced positive results from FASCINATE-1, the Phase 2 clinical trial of its oral, once-daily FASN inhibitor TVB-2640, the company's lead product candidate that is currently being evaluated as a potential treatment for ...